Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
Adolescent
Adult
Allografts
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Asparaginase
/ administration & dosage
Combined Modality Therapy
Cranial Irradiation
Cyclophosphamide
/ administration & dosage
Cytarabine
/ administration & dosage
Dexamethasone
/ administration & dosage
Disease-Free Survival
Doxorubicin
/ administration & dosage
Female
Hematopoietic Stem Cell Transplantation
Humans
Italy
/ epidemiology
Kaplan-Meier Estimate
Male
Mercaptopurine
/ administration & dosage
Methotrexate
/ administration & dosage
Neoplasm, Residual
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Prednisone
/ administration & dosage
Treatment Outcome
Vincristine
/ administration & dosage
Young Adult
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
07
10
2020
revised:
19
11
2020
accepted:
01
12
2020
pubmed:
8
12
2020
medline:
18
3
2021
entrez:
7
12
2020
Statut:
ppublish
Résumé
Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) represent a unique patient population with specific characteristics and needs. Growing evidences suggest that pediatric-inspired approaches improve the outcome in AYA. These results prompted the design of a pediatric AIEOP-BFM ALL 2000-based regimen - the GIMEMA LAL-1308 protocol - for newly diagnosed AYA (range 18-35 years) with Philadelphia negative (Ph-) ALL. The protocol included minimal residual disease (MRD) analysis at two different time-points (TP), that is, at the end of induction IA and consolidation IB, and a modulation in post-consolidation intensity according to MRD. Seventy-six patients were eligible between September 2010 and October 2014. The regimen was well tolerated, with 2.7% induction deaths and no deaths in the post-consolidation phase. The complete response (CR) rate was 92%; the 48-month overall survival (OS) and disease-free survival (DFS) were 60.3% and 60.4%. Both OS and DFS were significantly better in T-ALL than B-ALL. A molecular MRD <10
Substances chimiques
Cytarabine
04079A1RDZ
Vincristine
5J49Q6B70F
Dexamethasone
7S5I7G3JQL
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Mercaptopurine
E7WED276I5
Asparaginase
EC 3.5.1.1
Prednisone
VB0R961HZT
Methotrexate
YL5FZ2Y5U1
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
292-301Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Boissel N, Baruchel A. Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children? Blood. 2018;132:351-361.
Muffly L, Lichtensztajn D, Shiraz P, et al. Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: a population-based study. Cancer. 2017;123:122-130.
Boissel N. How should we treat the AYA patient with newly diagnosed ALL? Best Pract Res Clin Haematol. 2017;30:175-183.
Siegel SE, Stock W, Johnson RH, et al. Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review. JAMA Oncol. 2018;4:725-734.
Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:21-29.
Hayakawa F, Sakura T, Yujiri T, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. 2014;4:e252. https://doi.org/10.1038/bcj.2014.72.
Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206-3214.
Conter V, Valsecchi MG, Parasole R, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood. 2014;123:1470-1478.
Vitale A, Guarini A, Ariola C, et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood. 2006;107:473-479.
Tafuri A, Gregorj C, Petrucci MT, et al. MDR1 protein expression in an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 2002;100:974-981.
Gregorj C, Ricciardi MR, Petrucci MT, et al. ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 2007;109:5473-5476.
Chiaretti S, Messina M, Grammatico S, et al. Rapid identification of BCR/ABL1-like acute lymphoblastic leukemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. Br J Haematol. 2018;181:642-652.
van der Velden VH, Cazzaniga G, Schrauder A, et al. European Study Group on MRD detection in ALL (ESG-MRD-ALL)Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604-611.
Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C; ESMO Guidelines CommitteeAcute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v69-v82.
Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a children cancer group B phase III trial. J Clin Oncol. 1993;11(3):527-537.
DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29:526-534.
Ribera JM, Morgades M, Montesinos P, et al. A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: results of the ALLRE08 PETEHMA trial. Cancer Med. 2020;9:2317-2329.
Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133:1548-1559.
Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008;26:1843-1849.
Gokbuget N, Beck J, Brandt K, et al. Significant improvement of outcome in adolescents and young adults (AYA) aged 15-35years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protocol: results of 1529 AYAs in two consecutive trials of the German Multicenter Study Group for adult ALL (GMALL). Blood. 2013;122:839-839.
Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606-615.
Rytting ME, Jabbour EJ, Jorgensen JL, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91:819-823.
Dhedin N, Huynh A, Maury S, et al. Allogeneic hematopoietic stem cell transplantation (HSCT) in adults with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): results from the Group for Research on adult ALL (GRAALL). Blood. 2013;122:552.
Dhedin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125:2486-2496.
Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high-risk B-ALL: a report from children's oncology group study AALL0232. Blood. 2015;126:964-971.
Barba P, Morgades M, Montesinos P, et al. Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. Eur J Haematol. 2019;102:79-86.
Maese L, Tasian SK, Raetz EA. How is the Ph-like signature being incorporated into ALL therapy? Best Pract Res Clin Haematol. 2017;30:222-228.
Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522-1531.